On August 7, Jiangsu Hengrui Pharmaceuticals Co.,Ltd. (ticker: 600276) responded to investor inquiries on its interactive platform, stating that the company consistently adheres to a strategy of technological innovation and global expansion. It is committed to developing its core business and maintaining long-term value through a solid operational foundation, ultimately benefiting shareholders with improved performance.

In research and development, the company has allocated over 25% of its annual revenue to R&D for many consecutive years. This investment supports a diversified and robust pipeline of innovative products. To date, Jiangsu Hengrui Pharmaceuticals Co.,Ltd. has secured approval for 26 Class 1 new drugs and 6 Class 2 new drugs in China. Additionally, over 100 proprietary innovative products are under clinical development, with more than 400 clinical trials conducted both domestically and internationally.

Regarding international expansion, the company's products are now commercialized in over 50 countries. Jiangsu Hengrui Pharmaceuticals Co.,Ltd. emphasizes a balanced approach of independent innovation and open collaboration, strengthening international partnerships while fostering internal growth. Over the past three years, the company has completed 13 overseas licensing deals for innovative drugs. It is also accelerating its independent global expansion by building an overseas team to enhance its clinical development and commercialization capabilities worldwide.

The company's board of directors approved a share buyback plan on August 20, 2025, utilizing its own funds to repurchase A-shares. These shares are intended for a future A-share employee stock ownership plan. The buyback is ongoing and will be conducted within the specified period, with timely disclosures on progress as required.